Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:46 AM
Ignite Modification Date:
2025-12-25 @ 1:46 AM
NCT ID:
NCT06864494
Eligibility Criteria:
Inclusion Criteria:
Common inclusion criteria:
* The patient must have given their free and informed consent and signed the consent form
* The patient must be a member or beneficiary of a health insurance plan
Adenomyosis + group:
* Female.
* Aged 40 (≥) to 55 (≤) years.
* Multiparous.
* Non-menopausal.
* Having an indication for a total inter-ovarian hysterectomy (excluding oncology).
* Suffering from adenomyosis.
Adenomyosis - group:
* Female.
* Aged 40 (≥) to 55 (≤) years.
* Multiparous.
* Non-menopausal.
* Having an indication for a total inter-ovarian hysterectomy (excluding oncology).
* Suffering from a functional pathology other than adenomyosis.
Control Group:
* Female.
* Aged 18 (≥) to 43 (≤) years.
* Nulliparous.
* Asymptomatic: absence of menometrorrhagia and pelvic pain.
* Support at the medically assisted procreation (MAP) center of the Nîmes University Hospital for male or idiopathic infertility.
* Indication to perform an endovaginal ultrasound as part of MAP management.
* Absence of uterine pathology visualized on endovaginal ultrasound.
Exclusion Criteria:
* History of autoinflammatory or autoimmune disease.
* History of atopic or asthmatic conditions.
* History of sleep apnea syndrome.
* Chronic or acute renal failure.
* Liver failure
* History of active neoplasia or cancer.
* Presence of a functional-looking ovarian cyst on imaging (endovaginal ultrasound and/or pelvic MRI).
* Taking nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or aspirin in the 15 days prior to L-PGDS concentration measurement
* Undergoing estrogen-progestin hormonal contraception.
Adenomyosis groups:
\- Contraindication to MRI.
Control Group:
\- Endovaginal ultrasound refused by the patient.
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
55 Years
Study:
NCT06864494
Study Brief:
Protocol Section:
NCT06864494